Physician profile
John E Rink
NPI 1518184951
$5,761.40
in general payments reported to CMS, 2019-2025
39 companies · $608 in 2025
The $608 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.68 · 2022: $445 · 2023: $4,080 · 2024: $615 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,262 · Consulting Fee: $1,155 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $700 · Travel and Lodging: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,261.71 |
| Consulting Fee | $1,155.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $700.00 |
| Travel and Lodging | $186.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,984.57 | 2022-2025 | Jakafi, Monjuvi |
| Cti Biopharma Corp. | $700.00 | 2023 | Vonjo |
| Novartis Pharmaceuticals Corporation | $325.83 | 2022-2025 | |
| Celgene Corporation | $278.07 | 2022-2025 | Reblozyl, Onureg, Opdivo |
| Eisai INC. | $249.92 | 2022-2023 | |
| Daiichi Sankyo INC. | $232.59 | 2023-2025 | Vanflyta, Enhertu |
| Genzyme Corporation | $179.94 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $176.07 | 2022-2025 | Keytruda, Welireg |
| Janssen Biotech, INC. | $156.67 | 2023-2025 | Tecvayli, Balversa, Erleada |
| Amgen INC. | $149.72 | 2023 | Kyprolis, Xgeva, Nplate |
| Takeda Pharmaceuticals U.S.A., INC. | $138.13 | 2022-2025 | Ninlaro, Iclusig, Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $124.32 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $110.98 | 2022-2023 | |
| Astellas Pharma US INC | $100.42 | 2022-2024 | Xospata |
| Genentech USA, INC. | $84.44 | 2023-2024 | Lunsumio, Polivy, Venclexta |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $82.12 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $79.59 | 2023-2025 | Ultomiris |
| Karyopharm Therapeutics INC. | $57.10 | 2023-2024 | Xpovio |
| Sobi, INC | $52.15 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $46.95 | 2023 | Epkinly, Imbruvica |
| Astrazeneca Pharmaceuticals Lp | $43.71 | 2023-2025 | Imfinzi, Enhertu |
| Adaptive Biotechnologies Corporation | $42.63 | 2024 | Clonoseq |
| Emd Serono, INC. | $34.45 | 2023 | Bavencio |
| Glaxosmithkline, LLC. | $33.80 | 2024-2025 | Ojjaara |
| Exelixis INC. | $32.11 | 2022-2023 | Cabometyx |
| Morphosys, US INC. | $28.90 | 2023 | Monjuvi |
| Syndax Pharmaceuticals, INC. | $24.21 | 2025 | |
| Recordati_rare_diseases_inc. | $21.42 | 2024 | Sylvant |
| Caris Mpi, INC. | $20.60 | 2025 | Mi Cancer Seek |
| Biolinerx USA, INC. | $20.30 | 2024 | Aphexda |
| E.R. Squibb & Sons, L.L.C. | $19.74 | 2022 | |
| Stemline Therapeutics INC. | $18.47 | 2023 | Orserdu |
| Apellis Pharmaceuticals, INC. | $18.41 | 2024 | Empaveli |
| Ipsen Biopharmaceuticals, INC | $17.92 | 2025 | Somatuline Depot, Onivyde |
| Pfizer INC. | $17.24 | 2024 | |
| Acrotech Biopharma INC. | $17.14 | 2023 | Beleodaq |
| Servier Pharmaceuticals LLC | $15.48 | 2025 | |
| Blueprint Medicines Corporation | $13.41 | 2022 | |
| Rigel Pharmaceuticals, INC. | $11.88 | 2023 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.